A Phase 3 interventional study of Asundexian (BAY2433334) and Placebo in Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke and High-risk Transient Ischemic Attack, sponsored by Bayer. Completed at 741 sites in 37 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-20.
Sponsored by Bayer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Ischemic Attack, Transient with a site in United States — 10 open to participants now, 14 under way, 1 of them phase 3. Ischemic Attack, Transient · United States.
Among the 88 studies in Ischemic Attack, Transient with a site in United States, this one is the 2nd largest by enrollment of the 65 interventional ones that give a count, is one of 3 that started in 2023, is one of 12 in phase 3, and was the 77th registered.
330 studies on the registry are indexed under Ischemic Attack, Transient; 72 are open to participants now.
Browse Ischemic Attack, Transient studies →10 of the 88 studies in Ischemic Attack, Transient with a site in United States are open now. Recruiting first, the newest first:
Washington University School of Medicine · Sites in United States
Ages 18+
Stanford University · Sites in United States
Ages 40+
Massachusetts General Hospital · Sites in United States
Ages 18–99
Kessler Foundation · Sites in United States
Ages 18–75
University of Alabama at Birmingham · Sites in United States
Ages 18–89
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 56 Ischemic Attack, Transient studies recruiting now, 38 (68%) set no upper age limit and 6 (11%) stop at 75 or younger; 6 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 5 · Phase 2 9 · Phase 3 16 · Phase 4 3
First in 1998; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12,327 is above the median of 220 across 179 interventional studies indexed under Ischemic Attack, Transient.
Median enrollment 202 across the 65 interventional studies, 318 across the 22 observational. Of the 63 that completed or were terminated, 32 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 88 have an industry lead sponsor. The 10 most frequent:
Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.
Of its 214 completed or terminated interventional studies of FDA-regulated products, 133 (62%) have results posted.
Bayer has 6 studies filed under Ischemic Attack, Transient — fewer than ten, so there is no comparison to draw.
3 of the studies in Ischemic Attack, Transient with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07414732Massachusetts General HospitalTesting the Effectiveness of a Novel Intervention to Improve Medication Adherence in Stroke Survivors | 2027-04-30 |
| NCT07916883Washington University School of MedicinePET-MR Imaging of Natriuretic Peptide Receptor C (NPR-C) in Carotid Atherosclerosis With 64Cu-NODAGA-CANF (Multisite) | 2027-05-31 |
| NCT02098265University of Wisconsin, MadisonA Closed Loop Neural Activity Triggered Stroke Rehabilitation Device | 2027-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 88 studies in Ischemic Attack, Transient with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had:
Anticoagulants are another type of medicine that prevents blood clots from forming by interfering with a process known as coagulation (or blood clotting).
The study treatment asundexian is a new type of anticoagulant currently under development to provide further treatment options. Asundexian aims to further improve the standard of care without increasing the risk of bleeding.
The main purpose of this study is to learn whether asundexian works better than placebo at reducing ischemic strokes in participants who recently had a non-cardioembolic ischemic stroke or TIA/mini-stroke when given in addition to standard antiplatelet therapy. A placebo is a treatment that looks like a medicine but does not have any medicine in it.
Another aim is to compare the occurrence of major bleeding events during the study between the asundexian and the placebo group. Major bleedings have a serious or even life-threatening impact on a person's health.
Dependent on the treatment group, the participants will either take asundexian or placebo once a day for at least 3 months up to 31 months.
Approximately every 3 months during the treatment period, either a phone call or a visit to the study site is scheduled on an alternating basis. In addition, one visit before and up to two visits after the treatment period are planned.
During the study, the study team will:
An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive asundexian.
Drug: Asundexian (BAY2433334)
Participants will receive placebo.
Drug: Placebo
Once daily, oral
Placebo to asundexian, once daily, oral
Number of Participants Who Had an Ischemic Stroke
A participant is counted if a first ischemic stroke occurred after randomization. A time-to-event analysis using a Cox proportional hazards model was used to compare treatment groups over the full follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had ISTH Major Bleeding
A participant is counted if a first ISTH (International Society on Thrombosis and Hemostasis) major bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke)
A participant is counted if a first stroke (ischemic or hemorrhagic) occurred after randomization during the on-treatment period. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Composite of Cardiovascular Death, Myocardial Infarction, or Stroke
A participant is counted if a first occurrence of cardiovascular death, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Composite of All-cause Mortality, Myocardial Infarction, or Stroke
A participant is counted if a first occurrence of all-cause mortality, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Disabling Stroke (mRS ≥3 at 90 Days)
A participant is counted if a first disabling stroke occurred after randomization. Disabling stroke is defined as a stroke of any type associated with a modified Rankin Scale (mRS) score ≥3 at 90 days after the recurrent stroke, or an increase of ≥1 point if the last available mRS before the recurrent stroke was ≥3. Fatal strokes are included. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Died (All-cause Mortality)
A participant is counted if death due to any cause occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had a Transient Ischemic Attack (TIA)
A participant is counted if a first transient ischemic attack (TIA) occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding
A participant is counted if a first occurrence of ISTH major bleeding or clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had ISTH Clinically Relevant Non-major Bleeding
A participant is counted if a first occurrence of ISTH clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Symptomatic Intracranial Hemorrhage
A participant is counted if a first symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Hemorrhagic Stroke
A participant is counted if a first hemorrhagic stroke occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Fatal Bleeding
A participant is counted if a first fatal bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Minor Bleeding
A participant is counted if a first occurrence of minor bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Composite of Ischemic Stroke or ISTH Major Bleeding
A participant is counted if a first occurrence of ischemic stroke or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Composite of Cardiovascular Death, Any Stroke, Myocardial Infarction, or ISTH Major Bleeding
A participant is counted if a first occurrence of cardiovascular death, any stroke (ischemic or hemorrhagic), myocardial infarction, or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had Composite of All-cause Mortality, Disabling Stroke, Fatal Bleeding, or Symptomatic Intracranial Hemorrhage
A participant is counted if a first occurrence of all-cause mortality, disabling stroke, fatal bleeding, or symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
Time frame: Up to 32 months
Number of Participants Who Had an Ischemic Stroke in the First 90 Days
A participant is counted if a first ischemic stroke occurred within 90 days after randomization. Time-to-event analysis was performed using a Cox proportional hazards model restricted to the first 90 days of follow-up to compare treatment groups.
Time frame: Up to 90 days
12327 participants were randomized. Of those 12254 received the study intervention (6124 asundexian and 6130 placebo). Overall, 12243 completed the study. Of 84 participants who did not complete the study, the primary reason was withdrawal of consent or lost to follow up. The study was conducted at 700 study centers in Asia, Europe, North America and South America, Australia and Israel between 26-Jan-2023 (first participant first visit) and 23-Oct-2025 (last participant last visit).
| Milestone | Asundexian | Placebo |
|---|---|---|
| Started | 6162 | 6165 |
| Treated | 6124 | 6130 |
| Participants valid for fas analysis | 6162 | 6165 |
| Participants valid for saf analysis | 6124 | 6130 |
| Completed | 6109 | 6134 |
| Not completed | 53 | 31 |
| Withdrew: Withdrawal by subject | 30 | 15 |
| Withdrew: Lost to follow-up | 23 | 16 |
A participant is counted if a first ischemic stroke occurred after randomization. A time-to-event analysis using a Cox proportional hazards model was used to compare treatment groups over the full follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had an Ischemic Stroke | 384 | 518 |
A participant is counted if a first ISTH (International Society on Thrombosis and Hemostasis) major bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had ISTH Major Bleeding | 117 | 107 |
A participant is counted if a first stroke (ischemic or hemorrhagic) occurred after randomization during the on-treatment period. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had All Stroke (Ischemic Stroke or Hemorrhagic Stroke) | 404 | 545 |
A participant is counted if a first occurrence of cardiovascular death, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Composite of Cardiovascular Death, Myocardial Infarction, or Stroke | 568 | 685 |
A participant is counted if a first occurrence of all-cause mortality, myocardial infarction, or stroke occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Composite of All-cause Mortality, Myocardial Infarction, or Stroke | 649 | 757 |
A participant is counted if a first disabling stroke occurred after randomization. Disabling stroke is defined as a stroke of any type associated with a modified Rankin Scale (mRS) score ≥3 at 90 days after the recurrent stroke, or an increase of ≥1 point if the last available mRS before the recurrent stroke was ≥3. Fatal strokes are included. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Disabling Stroke (mRS ≥3 at 90 Days) | 128 | 185 |
A participant is counted if death due to any cause occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Died (All-cause Mortality) | 248 | 253 |
A participant is counted if a first transient ischemic attack (TIA) occurred after randomization. Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had a Transient Ischemic Attack (TIA) | 124 | 145 |
A participant is counted if a first occurrence of ISTH major bleeding or clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants With Composite of ISTH Major or Clinically Relevant Non-major Bleeding | 339 | 307 |
A participant is counted if a first occurrence of ISTH clinically relevant non-major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had ISTH Clinically Relevant Non-major Bleeding | 231 | 210 |
A participant is counted if a first symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Symptomatic Intracranial Hemorrhage | 41 | 36 |
A participant is counted if a first hemorrhagic stroke occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Hemorrhagic Stroke | 13 | 20 |
A participant is counted if a first fatal bleeding event occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Fatal Bleeding | 14 | 8 |
A participant is counted if a first occurrence of minor bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Minor Bleeding | 479 | 512 |
A participant is counted if a first occurrence of ischemic stroke or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Composite of Ischemic Stroke or ISTH Major Bleeding | 430 | 529 |
A participant is counted if a first occurrence of cardiovascular death, any stroke (ischemic or hemorrhagic), myocardial infarction, or ISTH major bleeding occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Composite of Cardiovascular Death, Any Stroke, Myocardial Infarction, or ISTH Major Bleeding | 518 | 611 |
A participant is counted if a first occurrence of all-cause mortality, disabling stroke, fatal bleeding, or symptomatic intracranial hemorrhage occurred after randomization during the on-treatment period (including 2 days after treatment discontinuation). Time-to-event analysis was performed using a stratified Cox proportional hazards model to compare treatment groups over the follow-up period.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had Composite of All-cause Mortality, Disabling Stroke, Fatal Bleeding, or Symptomatic Intracranial Hemorrhage | 189 | 234 |
A participant is counted if a first ischemic stroke occurred within 90 days after randomization. Time-to-event analysis was performed using a Cox proportional hazards model restricted to the first 90 days of follow-up to compare treatment groups.
| Participants | Asundexian | Placebo |
|---|---|---|
| Number of Participants Who Had an Ischemic Stroke in the First 90 Days | 183 | 218 |
Collected over After the first intake of study intervention up to 2 days after the last intake of study intervention, up to 32 months.. Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Asundexian | 248/6,162 (4%) | 1,177/6,124 (19.2%) | 2,600/6,124 (42.5%) |
| Placebo | 253/6,165 (4.1%) | 1,196/6,130 (19.5%) | 2,667/6,130 (43.5%) |
| Event | Asundexian | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 54/6124 | 65/6130 |
| Urinary tract infectionInfections and infestations | 36/6124 | 22/6130 |
| Atrial fibrillationCardiac disorders | 31/6124 | 33/6130 |
| Acute kidney injuryRenal and urinary disorders | 26/6124 | 32/6130 |
| SyncopeNervous system disorders | 26/6124 | 23/6130 |
| Cardiac failureCardiac disorders | 24/6124 | 12/6130 |
| Carotid artery stenosisNervous system disorders | 20/6124 | 22/6130 |
| COVID-19Infections and infestations | 20/6124 | 16/6130 |
| DeathGeneral disorders and administration site conditions | 13/6124 | 20/6130 |
| FallInjury, poisoning and procedural complications | 18/6124 | 14/6130 |
| Event | Asundexian | Placebo |
|---|---|---|
| ConstipationGastrointestinal disorders | 346/6124 | 381/6130 |
| Atrial fibrillationCardiac disorders | 277/6124 | 290/6130 |
| HypertensionVascular disorders | 232/6124 | 269/6130 |
| Urinary tract infectionInfections and infestations | 199/6124 | 217/6130 |
| HeadacheNervous system disorders | 189/6124 | 211/6130 |
| DiarrhoeaGastrointestinal disorders | 205/6124 | 166/6130 |
| InsomniaPsychiatric disorders | 177/6124 | 183/6130 |
| NasopharyngitisInfections and infestations | 176/6124 | 168/6130 |
| DizzinessNervous system disorders | 175/6124 | 160/6130 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 159/6124 | 157/6130 |
| Age, Continuous(Years) | Asundexian | Placebo | Total |
|---|---|---|---|
| Mean | 67.7 ± 10.8 | 67.5 ± 10.9 | 67.6 ± 10.8 |
| Sex: Female, Male(Participants) | Asundexian | Placebo | Total |
|---|---|---|---|
| Female | 2063 | 2047 | 4110 |
| Male | 4099 | 4118 | 8217 |
| Ethnicity (NIH/OMB)(Participants) | Asundexian | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 518 | 513 | 1031 |
| Not Hispanic or Latino | 5460 | 5459 | 10919 |
| Unknown or Not Reported | 184 | 193 | 377 |
| Race (NIH/OMB)(Participants) | Asundexian | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 55 | 74 | 129 |
| Asian | 1721 | 1742 | 3463 |
| Native Hawaiian or Other Pacific Islander | 3 | 4 | 7 |
| Black or African American | 143 | 139 | 282 |
| White | 4105 | 4078 | 8183 |
| More than one race | 28 | 16 | 44 |
| Unknown or Not Reported | 107 | 112 | 219 |
Showing the first 100 of 741 sites across 37 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA "Principles for responsible clinical trial data sharing". This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Ran from Jan 2023 to primary completion in Oct 2025, 32 months.
Results were first posted in Nov 2026, 1 year after primary completion.
Of 14 phase 3 interventional studies under Ischemic Attack, Transient, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 51. This study's 32 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Asundexian